Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2011-03-03 Board/Management Inform…
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Michael Glos, Bundeswirtschaftsminister a.D., wird Beirat der Nanohale AG
Board/Management Information Classification · 100% confidence The document is a short news release dated March 3, 2011, announcing that Michael Glos, a former German Minister of Economics, is joining the advisory board (Beirat) of Nanohale AG as a Senior Strategic Advisor. The key subject is a change in senior personnel/advisory structure. This directly matches the definition for Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2011-03-03 German
Russische Insulin-Experten zu Gast bei Nanohale AG in Dortmund
Regulatory Filings Classification · 100% confidence The document is a short press release dated February 9, 2011, distributed via DGAP, announcing a visit by Russian insulin experts to Nanohale AG and detailing a joint venture/collaboration with the Russian state corporation Rostechnologii regarding drug development (specifically insulin). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed financial report (IR). It is a general corporate announcement concerning business development, international cooperation, and future project milestones. Since it doesn't fit the specific categories like MANG (Board change), DIRS (Insider trade), or CAP (Financing), and it is a news item about business activities, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate news announcements that are not covered by more specific codes, especially when they are short news items distributed via a news service like DGAP.
2011-02-09 German
Nanohale AG fuhrt heute Borsenlisting durch
Delisting Announcement Classification · 100% confidence The document is a short corporate news release dated December 20, 2010, announcing that Nanohale AG's shares were admitted for trading on the Open Market (Freiverkehr) of the Frankfurt Stock Exchange. Key phrases include 'Börsenlisting durch' (Stock Exchange Listing) and details about the prospectus approval by BaFin and the first trading price. This event signifies a capital market transaction, specifically an initial listing or admission to trading. Reviewing the definitions, 'Capital/Financing Update' (CAP) covers fundraising and capital structure changes, which an IPO/listing falls under. Since this is a direct announcement of the listing event itself, and not a general regulatory filing (RNS) or a report (like 10-K or IR), CAP is the most appropriate classification for a listing announcement.
2010-12-20 German

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.